Lilly lowers Insulin Prices, Pursues Clinical Trials for COVID Therapy
- April 21, 2020
- 0 Comments
In this series we’re highlighting firms that are helping make things better during the COVID-19 pandemic. Eli Lilly (Lilly) is one such firm:
First, they’re lowering insulin costs to $35/month as a cap to out-of-pocket costs to help diabetes patients across the USA, who may be adversely impacted either economically or medically.
“Enabling a $35-per-month insulin co-pay regardless of employment status will help many Americans in this difficult time,” said CEOs Aaron Kowalski and Thom Scher of non-profit organization JDRF-Beyond Type 1 Alliance.
Second, they’re aiming for a faster way to get this new therapy into clinical trials within 4 months:
AbCellera and Lilly will split initial development costs. Beyond that, Lilly will take over and try to get the candidate through development, manufacturing and talks with regulators as quickly as possible. The early steps in that process could proceed faster than is typical under normal circumstances.
“While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months,” Lilly Chief Scientific Officer Daniel Skovronsky said in a statement.
Therapies like this, if they work, hold out the promise of treating an ill patient who has COVID-19. The news coverage indicates trials for these types of therapies can proceed faster than a general-population-use vaccine.
I’m sure this just scratches the surface for a firm like Lilly, but we’re very grateful for the moves they are making to help.